Specific inhibitor to KRAS^G12C induces tumor-specific immunity and synergizes with oncolytic virus for enhanced cancer immunotherapy.

ABSTRACT:

Background

Oncolytic virus (OV)-mediated immunotherapy has been shown limited efficacy. Small molecule inhibitors specific to the KRAS^G12C driver oncoprotein have recently been developed for cancer treatment. The combination of a potent OV with a KRAS^G12C inhibitor could be a potent combination strategy for treating KRAS^G12C cancer.

Methods

We explored combination therapies using KRAS^G12C inhibitor and OV in cancer cells in vitro and in two KRAS^G12C cancer models. We employed flow cytometry to evaluate the immune cell profiles, including dendritic cells, macrophages, myeloid-derived suppressor cells, natural killer (NK), subsets of CD4⁺ and CD8⁺ T cells, and exhaustion markers (CTLA-4, PD-1, TIM-3),

SUBMITTER: Zhu Z 

PROVIDER: S-EPMC12306217 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature